For resectable colorectal liver metastases, five-year survival rates similar with laparoscopic, open surgery<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Nov. 17, 2020 (HealthDay News) — For patients with metastatic colorectal cancer who have resectable liver metastases, survival outcomes at five years do not differ significantly for treatment with laparoscopic versus open liver resection, according to a study published online Nov. 17 in the Annals of Internal Medicine<\/em>.<\/p>\n Davit L. Aghayan, M.D., from the University of Oslo in Norway, and colleagues examined long-term oncologic outcomes after laparoscopic versus open liver resection in a single-center trial involving 280 patients with resectable colorectal liver metastases. Patients were randomly assigned to either laparoscopic surgery (133 patients) or open surgery (147 patients).<\/p>\n The researchers found that the rates of five-year survival were 54 and 55 percent in the laparoscopic and open groups, respectively, at a median follow-up of 70 months (hazard ratio, 0.93; 95 percent confidence interval, 0.67 to 1.30; P = 0.67). In the laparoscopic and open groups, the rates of five-year recurrence-free survival were 30 and 36 percent, respectively (hazard ratio, 1.09; 95 percent confidence interval, 0.80 to 1.49; P = 0.57).<\/p>\n “A limitation of our trial is that it was not powered to detect differences in secondary end points and was not designed to address a noninferiority hypothesis for survival outcomes,” the authors write. “Therefore, small-to-moderate differences in survival outcomes (in favor of either laparoscopic or open surgery) cannot be excluded, and clinicians should be aware of this when interpreting our results.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n